share_log

424B3: Prospectus

SEC ·  Jun 27 20:22
Summary by Futu AI
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.